Home > Drugs A – Z > Lanreotide (Under the skin)

Lanreotide (Under the skin)

Treats acromegaly (a growth hormone disorder) and tumors in the stomach, bowels, or pancreas.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Lanreotide injection is used for the long-term treatment of acromegaly (a growth hormone disorder) in patients who cannot be treated with surgery or radiation. This medicine works by reducing the amount of growth hormone that the body produces. This medicine is also used to treat neuroendocrine tumors from the gastrointestinal tract or the pancreas (GEP-NET) that has spread or cannot be removed… Read more
Brand names include
Somatuline Depot
Drug classes About this
Endocrine-Metabolic Agent

What works? Research summarized

Evidence reviews

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review

This review examined data on the tumour shrinkage effects of long-acting lanreotide in patients with acromegaly. It concluded that lanreotide was able to quite frequently induce tumour shrinkage, particularly when used as first-line therapy. Because of several reporting limitations, it is not possible to determine the reliability of this conclusion.

End of Life Care for Infants, Children and Young People with Life-Limiting Conditions: Planning and Management

This guideline covers the physical, emotional, social and spiritual elements of end of life care, and focuses on improving the child or young person’s quality of life and supporting their family and carers. There are, for instance, recommendations on managing distressing symptoms and providing care and bereavement support after death. Recommendations have also been made about how services should be delivered. The guideline is aimed at all providers of paediatric end of life care, whatever their level of practise, and also for children and young people with life-limiting conditions and their parents or carers.

Systematic review and meta-analysis of the role of somatostatin and its analogues in the treatment of enterocutaneous fistula

OBJECTIVE: Somatostatin analogues may help pancreatic fistula although it remains unclear whether they help nonpancreatic fistula. This study involved meta-analysis of somatostatin analogues for treatment of enterocutaneous fistula.

See all (8)

Summaries for consumers

Gastrointestinal Carcinoid Tumors Treatment (PDQ®): Patient Version

Expert-reviewed information summary about the treatment of gastrointestinal carcinoid tumors.

PubMed Health Blog...

read all...